Please login to the form below

Not currently logged in
Email:
Password:

Chris Bowden joins Agios

He is former VP, product development oncology at Genentech
Agios Chris Bowden

Agios Pharma has named former Genentech VP Chris Bowden as chief medical officer.

Bowden spent eight years at Genentech as VP, product development for its oncology unit. During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

Both drugs are now marketed by Roche since its takeover of Genentech in 2009.

Bowden's knowledge of oncology will benefit Agios as it prepares to advance the development of three candidates focused on cancer and inborn errors of metabolism.

“Agios is leading the investigation of precision medicine in the field of cellular metabolism, and has rapidly advanced several promising oral medicines to treat a range of serious diseases,” said Bowden.

Prior to working for Genentech Bowden spent three years as executive director for EMEA for Bristol-Myers Squibb. His earlier industry career includes spells as Janssen and Pharmacia.

15th May 2014

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

The gene therapy revolution
Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...

Infographics